We are live on
!
Find out more
ARRY
Array Biopharma Inc
ARRY
ARRY
Delisted
ARRY was delisted on the 29th of July, 2019.
268 hedge funds and large institutions have $5.5B invested in Array Biopharma Inc in 2019 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 101 increasing their positions, 75 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
338% more call options, than puts
Call options by funds: $89.5M | Put options by funds: $20.4M
114% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 29
83% more capital invested
Capital invested by funds: $3B → $5.5B (+$2.5B)
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
35% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 75
14% more funds holding
Funds holding: 236 → 268 (+32)
Holders
268
Holders Change
+32
Holders Change %
+13.56%
% of All Funds
5.8%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.28%
New
62
Increased
101
Reduced
75
Closed
29
Calls
$89.5M
Puts
$20.4M
Net Calls
+$69.1M
Net Calls Change
+$50.4M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$123M |
| 2 |
PA
Perceptive Advisors
New York
|
+$88M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$52.9M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$41.6M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$33.4M |
